In addition, this study indicated that although COVID-19 patients with severe illness in the first days from symptoms onset exhibited augment of IL-6 and IL-10, at late days from symptoms onset, they showed increased levels of IFN-α and IFN- λ, IL-17, IL-22, eotaxin, IL-13, and a reduction of IL-6. The gene discussed is IL17A; the disease is COVID-19.